Cytokinetics
CYTK · Biotechnology
$61.23
1.8%Krystal Biotech
KRYS · Biotechnology
$311.50
2.7%The short version
- Krystal Biotech is the larger business, with $389M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 4.4 times as much.
- Cytokinetics grew revenue faster (376.6%, against 33.9%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against −695.4% operating margin).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against −607.5% FCF margin).
| Latest fiscal year | CYTK · FY25 | KRYS · FY25 |
|---|---|---|
| Size | ||
| Market cap | — | $9.6B |
| Revenue | $88.0M | $389M |
| Free cash flow | −$535M | $189M |
| Net income | −$785M | $205M |
| Growth | ||
| Revenue growth | 376.6% | 33.9% |
| 5-year growth | 9.5% | — |
| Share count change | — | 0.7% |
| Profitability | ||
| Gross margin | — | — |
| Operating margin | −695.4% | 41.5% |
| Net margin | −891.6% | 52.6% |
| FCF margin | −607.5% | 48.6% |
| Return on capital | — | 43.6% |
| Return on equity | — | 18.9% |
| Balance sheet | ||
| Net debt | −$912M | −$828M |
| Net debt / EBITDA | — | −5.0x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | — | 39.0x |
| Piotroski F-score | — | 5 |
FY16
CYTK $106M
KRYS —
FY17
CYTK $13.4M
KRYS —
FY18
CYTK $31.5M
KRYS —
FY19
CYTK $26.9M
KRYS —
FY20
CYTK $55.8M
KRYS —
FY21
CYTK $70.4M
KRYS $0.0M
FY22
CYTK $94.6M
KRYS $0.0M
FY23
CYTK $7.5M
KRYS $50.7M
FY24
CYTK $18.5M
KRYS $291M
FY25
CYTK $88.0M
KRYS $389M
CYTK
KRYS
FY16
CYTK 17.6%
KRYS —
FY17
CYTK −848.3%
KRYS —
FY18
CYTK −282.3%
KRYS —
FY19
CYTK −368.0%
KRYS —
FY20
CYTK −168.3%
KRYS —
FY21
CYTK −264.5%
KRYS —
FY22
CYTK −342.8%
KRYS —
FY23
CYTK −6,589.7%
KRYS −216.2%
FY24
CYTK −2,902.7%
KRYS 22.6%
FY25
CYTK −695.4%
KRYS 41.5%
CYTK
KRYS
FY16
CYTK $35.4M
KRYS −$1.3M
FY17
CYTK −$105M
KRYS −$4.1M
FY18
CYTK −$102M
KRYS −$11.7M
FY19
CYTK −$93.5M
KRYS −$25.1M
FY20
CYTK −$2.1M
KRYS −$40.9M
FY21
CYTK −$191M
KRYS −$116M
FY22
CYTK −$311M
KRYS −$154M
FY23
CYTK −$416M
KRYS −$101M
FY24
CYTK −$400M
KRYS $119M
FY25
CYTK −$535M
KRYS $189M
CYTK
KRYS
FY16
CYTK —
KRYS —
FY17
CYTK —
KRYS —
FY18
CYTK —
KRYS —
FY19
CYTK —
KRYS —
FY20
CYTK —
KRYS —
FY21
CYTK —
KRYS −61.2%
FY22
CYTK —
KRYS −76.9%
FY23
CYTK —
KRYS −47.7%
FY24
CYTK —
KRYS 20.7%
FY25
CYTK —
KRYS 43.6%
CYTK
KRYS
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.